Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon
Details
Publication Year 2024-03-26,Volume 8,Issue #6,Page 1439-1443
Journal Title
Blood Advances
Publication Type
Research article
Publisher
American Society of Hematology
Keywords
Humans; Rituximab/therapeutic use; *Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy; Neoplasm Recurrence, Local; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use; *Sulfonamides
Department(s)
Clinical Haematology; Pathology
Open Access at Publisher's Site
https://doi.org/10.1182/bloodadvances.2023011327
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-04-04 03:09:38
Last Modified: 2024-04-04 03:11:20

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙